February 16th, 2016 / Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT) announced in a news release dated December 21, 2015, that the Company would invest in Cannevert Therapeutics Ltd. (“CTL”) to assist in the discovery and development of new cannabis cultivars for specific disease conditions.
Below are the key Cannevert scientists:
Michael J. A. Walker, PhD
He is Cannevert’s President and Head of Biology. He is also an Emeritus Professor at University of British Columbia (UBC) with expertise in general pharmacology, toxins, pharmacology of excitable tissues as well as drug design and development. He holds numerous patents and has founded several public and private companies in Canada and the United Kingdom including Cardiome Pharma Corp. (TSX: COM), Verona Pharma plc (LSE-AIM: VRP), and Pneumolabs.
Bernard A. MacLeod, MD
He is Cannevert’s Senior Clinical Scientist. He is a UBC Emeritus Professor with a long career as an anesthesiologist with 30 years of experience in preclinical and clinical pharmacology research. He was former Head of Anesthesiology at University Hospital and at the British Columbia Cancer Agency. He is co-holder of patents in the areas of anti-arrhythmic drugs, analgesic drugs and computer techniques for mathematical modelling of anesthetic depth and prediction of epilepsy. Dr. MacLeod has previously contributed as director and scientific advisor to Cardiome Pharma Corp. (TSX: COM).
Richard A. Wall, PhD
He is the company’s Principal Chemist and also a UBC Emeritus Professor. He was originally trained with honors in chemistry at the University of California and received a Ph.D. degree in synthetic organic chemistry from the University of Edinburgh. His interest in natural products and drugs grew in subsequent years as a lecturer in organic chemistry at the University of Edinburgh. In Canada, at UBC, he combined his analytical skills and organic chemical background for new drug development, and was instrumental in the scientific foundation of Cardiome Pharma Corp. (TSX: COM). He presently consults on the legal aspects of drug use and particularly on medicinal chemistry for pharmaceutical companies. These activities have produced more than 70 scientific papers and authorship of 20 patents on analytical and medicinal chemistry.
Ernest Puil, PhD
He is a Pharmacology Consultant who is also an active Emeritus Professor at UBC. He has an international reputation in CNS pharmacology and the current CEO of Therexcell Pharma Inc. His laboratory is internationally known for research on central nervous system function and disorders, and pharmacological basis of therapy. He is a co-holder of patents on potential therapeutic uses of compounds and techniques for prediction of epileptic seizures. Previously, Dr. Puil served as director of former Capital Pool companies. He acts as a consultant on central nervous system drugs to pharmaceutical and biotech companies globally.
Thomas Stokes, PhD
He is one of Cannevert’s Chemistry Consultants. He is both a chemistry expert and ethnopharmacologist with extensive corporate experience, primarily in implementing biological methodologies for enhancing yields in traditional industries. Dr. Stokes is an enzymologist with training in biochemistry at Rice University in Houston, Texas. His entrepreneurial companies have pioneered diverse ventures such as off-bottom oyster culture and the use of enzymes in synthesis of chiral chemicals. He was president of Biota Control Inc. which focused on the use of pheromones to control insects. He directs sales for Biofine International Inc., which specializes in the custom synthesis of compounds for the pharmaceutical industry. He is also the chief medicinal chemist at Therexcell Pharma Inc.
Andrew Hegle, PhD
He is one of Cannevert’s Senior Scientists. He is currently a UBC Adjunct Professor who received his PhD in with expertise in in molecular, cellular and developmental biology from the University of Michigan. He trained as a postdoctoral fellow at UBC, and has a strong background in experimental electrophysiology, pharmacology and biochemistry, with special emphasis on the molecular mechanisms that regulate ionotropic membrane receptors. His experience is in developing industrial analytical chemistry systems and he helped to establish the first cannabinoid research laboratory at the UBC Department of Pharmacology.
Ricardo Rivera-Acevedo, PhD
He is also a Senior Scientist and a UBC Adjunct Professor with a strong background in experimental pharmacology and pathophysiology. He received his Bachelor’s Degree in Biomedical Sciences from the University of Puerto Rico - Cayey. He went on to earn a Ph.D. in Pharmacology from UBC, designing novel pharmacological approaches to pain control and chronic pain management techniques using experimental ionotropic cannabinoid receptor antagonists. As a UBC postdoctoral fellow he studied cardiac pharmacology and pathophysiology, before joining the Department of Pharmacology in 2014 where he established the department's first analytical laboratory for cannabinoid research.
Dr. Walker stated that “both the financing and expertise that Veritas Pharma is providing Cannevert will enable us to take the necessary steps in discovering and developing new cultivars that we can quickly take to market. Veritas’s CEO, Dr. Lui Franciosi has full confidence in our abilities to discover new treatments that actually make money for investors.”
Dr. Franciosi commented, “The strategic alliance that we’ve formed with Cannevert will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants will be patent protected for a variety of unmet medical needs. These scientists have indeed the rare skills necessary to make blockbuster medicines.
More information about Cannevert Therapeutics Ltd. can be found at http://www.cannevert.com
About VERITAS Pharma Inc
Veritas Pharma Inc (trading symbol CSE:VRT) is an early stage pharmaceutical company developing innovative cannabinoid prescription medicines to treat medical conditions such as pain, emesis (nausea/vomiting), glaucoma, and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate medicines using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).
On behalf of the Board of Directors
Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Office
Investor and Public Relations Contact
Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
The CSE has not reviewed, nor approved or disapproved the content of this press release.
This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including future plans for development of technologies by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer